HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Key facts

Sponsor

Princess Maxima Center for Pediatric Oncology

Principal Investigator

Michel Zwaan, Prof. Dr.

Princess Máxima Center

Intervention

Ruxolitinib(drug)

Enrollment

26 enrolled

Eligibility

1-21 years · All sexes

Timeline

2025 – 2032

Study locations (30)

• St. Anna Kinderspital, Vienna, Austria
• Universitair Ziekenhuis Gent, Ghent, Belgium
• Rigshospitalet Copenhagen, Copenhagen, Denmark
• Helsinki University Hospital, New Children's Hospital, Helsinki, Finland
• Hôpital des Enfants GH Pellegrin - CHU de Bordeaux, Bordeaux, France
• CHRU Lille - Hôpital Jeanne de Flandre, Lille, France
• Centre Léon Bérard, Lyon, France
• Hopital La Timone - Enfants, Marseille, France
• CHU Nantes Hôpital Mère-Enfant, Nantes, France
• Hôpital Robert Debré, Paris, France
• Universitätsklinikum Augsburg, Augsburg, Germany
• Charité Universitätsmedizin Berlin, Berlin, Germany
• Universitätsklinikum Essen, Essen, Germany
• Universitätsklinikum Frankfurt, Frankfurt, Germany
• Universitätsklinikum Münster, Münster, Germany
• +15 more locations on ClinicalTrials.gov

Collaborators

Innovative Therapies For Children with Cancer Consortium · IBFM · Fight Kids Cancer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult T-cell leukemia/lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07388563
  Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT07159620
  Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE1NCT07108868
  A Phase I Dose Finding Study of MB-CART2219.1
  University Hospital Tuebingen
• RECRUITINGNCT05237986
  Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT07008885
  BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
  Chinese PLA General Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT07541755
  PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL
  Fujian Medical University Union Hospital
• RECRUITINGPHASE2NCT06698003
  A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE2NCT06598722
  BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

See all trials for Adult T-cell leukemia/lymphoma →